This site uses cookies for learning about our traffic, we store no personal details. ACCEPT COOKIES DECLINE COOKIES What are cookies?
univerge site banner
Original Article | Open Access | Am. J. Pure Appl. Sci., 2021; 3(4), 85-97. | doi: 10.34104/ajpab.021.085097

More to Explore; The Mesenchymal Stem Cells (MSCs) Major Tissue Sources, Known Surface Markers and Its Immunomodulation properties

Kanwal Abbasi Mail Img ,
Samina Iqbal ,
Saeeda Bano ,
Kausar Siddiqui ,
Lovely Muthiah

Abstract

Mesenchymal stem cells (MSCs) are currently available for a range of applications and have become a good material for regenerative medicine, tissue engineering, and disease therapy. MSCs are self-renewing, multipotent progenitor cells with multilineage potential to differentiate into cell types of mesodermal origin, such as adipocytes, osteocytes, and chondrocytes, and exert potent immunosuppressive potentials. In the present review, we highlight the currently reported variations in the differentiation potential of MSCs from different tissue sources, the minimal criteria to define MSCs from various tissue environments, and provide a detailed description of MSCs surface markers. Furthermore, MSCs immunomodulatory features secrete cytokines and immune receptors which regulate the microenvironment in the host tissue also revisits in detail. We propose that there are likely more sources of MSCs waiting to be discovered. We need to Standardize MSCs characterization by selecting markers for isolation, cellular and molecular mechanisms involved in MSC-mediated immune modulation, and other functionalities of MSCs should be characterized prior to use in clinical applications. 

INTRODUCTION

Stem cells represent a novel cell type in the body. Stem cells have two features: the ability to differentiate along different lineages and the ability to self-renew and maintain tissue homeostasis. Stem cells can be multi-plied in large Stem cells are broadly classified based on their source into embryonic (hESCs) and adult (ASCs) stem cells. Bhartiya, (2013) Embryonic stem cells are pluripotent in nature and can be differentiated into 200 odd cell types where as the  adult stem cells are isolated from adult body tissues and are multi-to unipotent in nature (Thomson et al., 1998). MSCs are adult stem cells which can be isolated from human and animal sources with the capacity to differentiate into meso-dermal lineage. MSCs and their multiline age were first found by Friedenstein via studies on the mouse bone marrow in the 1960s (Friedenstein et al., 1987; Frie-denstein et al., 1976; Friedenstein, 1966). 

The multiline age differentiation potential of adult human MSCs from bone marrow was described by Pittenger and group. They have been isolated from almost all tissues including per vascular area (Pittenger et al., 1999). In view of many studies till now, neither single definition nor a quantitative assay to help in the identification of MSCs in mixed population of cells is available; some biomarkers are available for identi-fication of human MSC (hMSC). In 2006 a set of mar-kers and cell characteristics has been proposed by the International Society for Cellular Therapy has proposed minimum criteria to define MSCs as these cells (a) should exhibits plastic adherence; (b) possess specific set of cell surface markers, i.e. cluster of differentiation CD73, D90, CD105 and lack expression of CD14, CD34, CD45 and human leucocyte antigen-DR (HLA-DR); and (c) have the ability to differentiate in-vitro into adipocyte, chondrocyte and osteoblast (Crisan et al., 2008). The availability and culturally expandable in vitro with special genomic stability and less ethical issues, marking these incredible cells importance in cell regenerative therapy and medicine (Dominici et al., 2006; Ullah et al., 2015). The resent study is the con-cise review article to gather available the information about stem cell sources, identification makers, Paracrine secretion, Immunomodulation by MSCs and their importance in regenerative therapies.

Human Mesenchymal Stem Cell (HMSC) Sources:

The bone marrow (BM) has been the prevailing source of MSCs in humans (Mushahary et al., 2018). How-ever, while BM is a rich source of hematopoietic stem cells, it constitutes only a rare MSC population (Li et al., 2016) BM-derived MSC (bmMSC) supply is the painful harvesting procedure marking   their application in research and in the clinical setting limited. Over time, a number of other tissues have been identified as alternative sources for hMSC. Today, MSC can be iso-lated from multiple tissues (Ullah et al., 2015). The human MSC (hMSC) properties can vary greatly depending on multiple parameters including tissue source, isolation method and medium composition and several studies mentioned variations in the differen-tiation potential of MSC from different tissue sources. Table 1 summaries some of the currently used tissue sources and the respective confirmed differentiation potentials.

Markers for MSC Identification and Verification:

The International Society for Cellular Therapy (ISCT) published the minimal criteria for defining MSCs in 2006. The ISCT proposed positive and negative mar-kers that enabled researchers to distinguish MSCs from other cells in the bone- marrow compartment. The negative markers were selected to include surface anti-gens that are expressed by hematopoietic cells, while the positive markers were selected to include surface antigens that are absent from most hematopoietic cells. It is well established that cultured colonies of MSCs ex-press CD105, CD73, and CD90, but do not express CD45, CD34, CD14 or CD11b, CD19, and HLA-DR (Datta et al., 2011; Karystinou et al., 2009) Table 2. Some labeling strategies have also been used to succ-essfully isolate MSCs enriched for markers such as STRO-1 (Saeedi et al., 2019; Gronthos et al., 2003; Kuroda et al., 2010; Psaltis et al., 2010) CD146 (Bensidhoum et al., 2004; Covas et al., 2008), SSEA-4 (da Silva Meirelles et al., 2015; Gang et al., 2007), CD271 (NGFR) (Battula et al., 2008; Vaculik et al., 2012) antigen 1 (MSCA-1). ISCT acknowledges that the criteria must be met with some flexibility, parti-cularly as they relate to expression of the negative mar-ker, HLA Class II. Specifically, HLA Class II can be expressed by MSCs under certain conditions, such as cytokine stimulation. Therefore, cells that meet all other criteria, but are also positive for HLA Class II, can be designated as MSCs if an adjective is used to indicate that the cells were stimulated. According to the ISCT, CD34 is a negative marker of MSCs. However, some reports suggest that the CD34 negative status is an artifact of cell culture condition (Pilbauerová et al., 2019). In fact, several groups have shown that MSCs isolated from adipose tissue express CD34 at the time of isolation but lose expression while in culture (Lin et al., 2012; Quirici et al., 2010). Expression of CD34 by MSCs is also supported by the fact that the STRO-1 antibody (Clone STRO-1), which is commonly used to identify MSCs, was developed using CD34+bone marrow as the immunogen (Pachón-Peña et al., 2011). The debate over the use of CD34 as a negative marker raises the possibility that markers may vary depending on the MSC tissue source (Kim & Cho, 2013). For specific immunophenotypic patterns, the variety of tissue sources of peripheral stem cells that could be iso-lated by their lineage-specific surface markers are summarized in Table 3.

Mesenchymal Stem Cell Markers Co-expression:

The purity of MSCs can be increased by using more than one MSC marker for positive selection. As an example, a recent publication demonstrated that selec-tion of mesenchymal stem cells using CD271/NGF R, CD90/Thy1, and CD106/VCAM-1 resulted in a highly clonogenic population of cells (Simmons & Torok-Storb, 1991). Specifically, the addition of CD106 as a marker for positive selection led to isolation of cells with five times greater clonogenic potential compared to the cells isolated with CD271/and CD90 alone. The degree of co expression of surface markers on MSCs also studied (Rasmusson et al., 2003). The cells sub-sets detected for the presence of MSCA-1/TNAP, CD271/NGF R and CD56/NCAM from whole cell population of   Human BM-MNCs were analyzed and reported that the CD271 expression detected and CD56 expression not detected cells expressed CD106 and CD146 whereas, CD271 and CD56 presences detected cells exclusively expressed CD166 (Mabuchi et al., 2013) CD271 and CD56 double positivity enriched SSEA-4 expression and MSCA-1 expression. The study conducted by Vaculik et al. (2012), explains the ex-pression pattern of SSEA-4 in dermis was analogous to CD271. CD271 and SSEA-4 both co expressed with CD45 detected cells, in human dermis where as CD73 and CD105 are co expressed. The human dermis minor population of CD73 detected cells are not expressed CD90 (Battula et al., 2008). Dermis CD271 positive cells were also positive for CD73and CD105, whereas the majority of CD271 positive cells are CD90 negative (Battula et al., 2008). Several other studies have been performed recently aimed at achieving high-purity BM MSCs using a combination of CD271 and markers other than CD73, CD105, or CD90 (Pérez-Silos et al., 2016) for example, CD146 has attracted a lot of interest recently, by linking CD146 expression on MSCs with their pericyte topography and function (Battula et al., 2009; Pittenger et al., 1999). It was also reported that CD146 expression on CD271 positive MSCs correlates more with their in situ localization (Sacchetti et al., 2007). Maijenburg further reported that the distribution of CD271 and CD146 and subsets correlates with donor age. The main subset in pediatric and fetal BM was reported to be CD271 expression and CD146 expres-sion, whereas the subset of CD271 expression and CD146 not expression detected population was domi-nant in adult marrow (Tormin et al., 2011). The endo-metrial MSC-like cells (eMSCs) can be purified on the basis of their co expression of two per vascular mar-kers, CD140b/platelet-derived growth factor receptor β (PDGFRβ) and CD146 (Maijenburg et al., 2012). The first novel single marker, W5C5 for isolation of endometrial MSC-like cells (eMSCs) (Schwab & Gargett et al., 2007; Masuda et al., 2012)

Immunomodulatory Properties of MSCS:

One of the main advantages of MSCs is their immuno-modulatory properties. MSCs grown in vitro have the ability to interact and regulate the function of the majority of effectors cells involved in the processes of primary and acquired immune response. Due to low ex-pression of MHC I and lack expression of MHC class II along with co-stimulatory molecules, like CD80, CD40 and CD86, MSCs are unable to bring substantial all reactivity and these features protects MSCs from natural killer (NK) cells lysis (Masuda et al., 2012). 

Moreover, it is observed that human BM-MSCs were not recognized by NK cells, as they expressed HLA-DR molecules (Rasmusson et al., 2003) MSCs exert immunomodulatory effects by inhibiting the com-plement-mediated effects of peripheral blood mono-nuclear cell proliferation (Spaggiari et al., 2006; Tu et al., 2010) blocking apoptosis of native and activated neutrophils, as well as reducing the number of neu-trophils binding to vascular endothelial cells, limiting the mobilization of these cells to the area of damage (Moll et al., 2011; Cassatella et al., 2011). In response to inflammatory molecules such as interleukin-1 (IL-1), IL-2, IL-12, tumor necrosis factor-a (TNF-α) and inter-feron-gamma (INF-ɣ), MSCs secrete an array of growth factors and anti-inflammatory proteins with complex feedback mechanisms among the many types of immune cells summarize in Table 4 (Munir et al., 2015; Shi et al., 2015; Cagliani et al., 2017; Weiss & Dahlke, 2019; Maria et al., 2017; Zhao et al., 2016). 

The key immunomodulatory cytokines include prosta-glandin 2, TGF-b1, HGF, SDF-1, nitrous oxide, indo-leamine 2,3-dioxygenase, IL-4, IL-6, IL-10,IL-1 rec- eptor antagonist and soluble tumor necrosis factor-a receptor (Murphy et al., 2013). MSCs prevent pro-liferation and function of many inflammatory immune cells, including T cells, natural killer cells, B cells, monocytes, macrophages and dendritic cells. MSCs can block the differentiation of CD34+ cells isolated from the bone marrow or blood monocytes into mature dendritic cells both by direct contact as well as by secreted paracrine factors (Nauta et al., 2006; Jiang et al., 2005). They inhibit the transformation of immature dendritic cells into mature forms and limit the mobi-lization of dendritic cells to the tissues. (Su et al., 2011) Due to the influence of MSCs, M1 (pro-inflammatory) macrophages are transformed into M2 type cells with an anti-inflammatory phenol-type, and the interleukin (IL)-10 secreted by them inhibits T-cell proliferation (Chen et al., 2014; Gao et al., 2014). 

In vitro studies have demonstrated a direct immune-modulatory effect of MSCs on lymphocytes by sup-pression of activated CD4+ and CD8+ T cells and B-lymphocytes was observed (Sharif et al., 2019; Glennie et al., 2005). In addition, MSCs reduce the level of pro-inflammatory cytokines synthesized by T-lymphocytes, such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ (Yañez et al., 2006) and increase synthesis of anti-inflammatory cytokines, for example, IL-4. MSCs also have the ability to limit the synthesis of immune-globulins like immunoglobulin (Ig) M, IgG, and IgA classes secreted by activated B cells, thereby blocking the differentiation of these cells to plasma cells (Corcione et al., 2006). MHC class I chain-like gene A (MICA) together with TLR3 ligand and other immune-regulatory proteins kept the MSCs safe from NKs invasion (Giuliani et al., 2014). Together with other properties, these immunomodulatory features makes MSCs one of the feasible stem-cells sources for performing cell transplantation experiments.

Furthermore, it is also important to note that MSCs from different sources may differ in their mechanisms and capacities for immune-modulation (Mattar & Bieback, 2015). Because of their trophic and immune-modulatory functions, MSCs are generally considered to possess greater advantages in cell-based regenerative medicine, MSCs an important regulator of the immune tolerance and attractive therapeutic target for limiting autoimmune inflammation.

CONCLUSION

Mesenchymal stem cells have been isolated from a wide range of species and tissues using several tech-niques. MSCs are isolated as a heterogeneous popu-lation of cells that differ in growth kinetics and differ-entiation potentials. A large number of markers have been brought forward to facilitate the isolation of MSCs from their surrounding environment or the selection of MSCs with high stemness. With their ability to differ-entiate into multiple lineages, secrete factors related to immune regulation, and migrate to-ward sites of infla-mmation, All these properties of MSCs make them distinct from other stem cells and can be used in future cell replacement therapy and many other clinical impli-cations. In this review, we concisely bring up the current data available for MSCs isolation sources, characterization markers and its immunomodulatory properties. The future MSCs research should focus on finding more suitable markers to isolate the source-specific MSCs, basic understanding of growth regu-lators in differentiation and trans-differentiation and its immunomodulatory properties to modify the host immune environment.

ACKNOWLEDGEMENT

The authors would like to express their gratitude Pakistan Council of Scientific and Industrial Research for their constructive cooperation throughout the research work.

CONFLICTS OF INTEREST

The authors wish to confirm that there are no conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Article References:

  1. An, S. Y.; Han, J.; Park, S. Y. (2014). Valproic acid promotes differentiation of hepatocyte-like cells from whole human umbilical cord-derived mesenchymal stem cells. Tissue Cell. 46(2), 127-135. https://doi.org/10.1016/j.tice.2013.12.006 
  2. Anzalone, R.; Lo Iacono, M.; Corrao, S. (2010). New emerging potentials for human Whartons jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capa-city. Stem Cells Dev 19(4), 423-38 https://doi.org/10.1089/scd.2009.0299  
  3. Baek, H.; Noh, Y. H.; Lee, J. H. (2014).  Auto-nomous isolation, long-term culture and differen-tiation potential of adult salivary gland-derived stem/progenitor cells. J Tissue Eng Regen Med. 8(9), 717-27. https://doi.org/10.1002/term.1572 
  4. Baglioni, S.; Squecco, R.; Lombardi, A. (2009). Characterization of human adult stem-cell popu-lations isolated from visceral and subcutaneous adipose tissue. FASEB J. 23(10), 3494-505. https://doi.org/10.1096/fj.08-126946  
  5. Bartsch, G.; Yoo, J. J.; Siddiqui, M. M. (2005). Propagation, expansion, and multi lineage differ-entiation of human somatic stem cells from der-mal progenitors. Stem Cells Dev. 14(3), 337-48.
  6. Barzilay, R.; Melamed, E.; Offen, D. (2009). Lentiviral delivery of LMX1a enhances dopami-nergic phenotype in differentiated human bone marrow mesenchymal stem cells. Stem Cells Dev. 18(4), 591-601.
  7. Battula, V. L.; Abele, H.; Bühring, H. J. (2008). Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. Differentiation 76(4), 326-36. https://doi.org/10.1111/j.1432-0436.2007.00225.x 
  8. Battula, V. L.; Treml, S.; Müller, I. (2009). Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica, 94(2), 173-84. https://doi.org/10.3324/haematol.13740  
  9. Bensidhoum, M.; Chapel, A.; Fouillard, L.; (2004). Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 103(9), 3313-9.
  10. Bhartiya, D. (2013). Are Mesenchymal Cells Indeed Pluripotent Stem Cells or Just Stromal Cells? OCT-4 and VSELs Biology Has Led to Better Understanding. Stem Cells Int 2013: 547501. https://doi.org/10.1155/2013/547501  
  11. Boxall, S. A.; Jones, E. (2012). Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012, 975871. https://doi.org/10.1155/2012/975871  
  12. Cagliani, J.; Grande, D.; Rilo, H. L. R. (2017). Immuno-modulation by Mesenchymal Stromal Cells and their Clinical Applications. J Stem Cell Regen Biol, 3(2). https://doi.org/10.15436/2471-0598.17.022  
  13. Cai, J.; Su, H.; Zhu, F. (2010). Generation of human induced pluripotent stem cells from um-bilical cord matrix and amniotic membrane mes-enchymal cells. J Biol Chem. 285(15), 11227-34. 
  14. Cassatella, M. A.; Mosna, F.; Lisi, V. (2011). Toll-like receptor-3-activated human mesenchy-mal stromal cells significantly prolong the sur-vival and function of neutrophils. Stem Cells, 29(6), 1001-11. https://doi.org/10.1002/stem.651 
  15. Chan, T. M.; Harn, H. J.; Lin, H. P.; Chou, P. W. (2014). Improved human mesenchymal stem cell isolation. Cell Transplant 23(4-5), 399-406. 
  16. Chen, P. M.; Liu, K. J.; Yen, B. L. (2014). Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepato-cyte growth factor through ERK1/2. J Leukoc Biol, 96(2), 295-303. https://doi.org/10.1189/jlb.3a0513-242r  
  17. Christodoulou, I.; Kolisis, F. N.; Zoumpourlis, V. (2013). Comparative evaluation of human mes-enchymal stem cells of fetal and adult origin during prolonged in vitro expansion: consider-ations for Cytotherapy. Stem Cells Int 2013, 246134. https://doi.org/10.1155/2013/246134 
  18. Choi, Y. S.; Dusting, G. J.; Aruno-thayaraj, S. (2010). Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med. 14(4), 878-89 https://doi.org/10.1111/j.1582-4934.2010.01009.x  
  19. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1), 367-72.https://doi.org/10.1182/blood-2005-07-2657   
  20. Covas, D. T.; Panepucci, R. A.; Fontes, A. M.  (2008). Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol 36(5), 642-54.
  21. Crisan, M.; Yap, S.; Andriolo, G. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 3(3), 301-13.https://doi.org/10.1016/j.stem.2008.07.003 
  22. da Silva Meirelles, L.;  Malta, T. M.;  Covas, D. T. (2015). Cultured Human Adipose Tissue Peri-cytes and Mesenchymal Stromal Cells Display a Very Similar Gene Expression Profile. Stem Cells Dev, 24(23), 2822-40. https://doi.org/10.1016/j.gdata.2015.11.009  
  23. Datta, I.; Mishra, S.; Joshi, P. G. (2011). Neu-ronal plasticity of human Whartons jelly mesen-chymal stromal cells to the dopaminergic cell type compared with human bone marrow mesen-chymal stromal cells. Cytotherapy 13(8), 918-32. 
  24. Djouad, F.; Bony, C.; Apparailly, F. (2005). Transcriptional profiles discriminate bone mar-row- derived and synovium-derived mesenchy-mal stem cells. Arthritis Res Ther, 7(6), R1304-15. https://doi.org/10.1186/ar1827  
  25. Dominici, M.; Le Blanc, K.; Horwitz, E. (2006). Minimal criteria for defining multipotent mesen-chymal stromal cells. The International Society for Cellular Therapy position statement. Cyto-therapy. 8(4), 315-7 https://doi.org/10.1080/14653240600855905  
  26. Friedenstein, A. J., Piatetzky-Shapiro, I. I.; Petra-kova, K. V. (1966). Osteogenesis in trans-plants of bone marrow cells. J Emb Exp Morphl, 16(3), 381-90. https://doi.org/10.1002/jcp.1040740209 
  27. Friedenstein, A. J., Chailakhyan, R. K.; Gerasi-mov, U. V. (1987). Bone marrow osteogenic stem cells: in vitro cultivation and transplan-tation in diffusion chambers. Cell Tissue Kinet, 20(3), 263-72. https://doi.org/10.1111/j.1365-2184.1987.tb01309.x  
  28. Friedenstein, A. J.; Gorskaja, J. F.; Kulagina, N. N. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol, 4(5), 267-74.
  29. Gabr, M. M.; Refaie, A. F.; Ghoneim, M. A. (2013). Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice. Cell Transplant. 22(1), 133-45. https://doi.org/10.1177/0963689718759913  
  30. Gang, E. J.;  Bosnakovski, D.;  Figueiredo, C. A.;  Visser, J. W.; Perlingeiro, R. C. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109(4), 174351
  31. Gao, S.; Mao, F.; Zhang, B.; Zhang, L. (2014). Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways. Exp Biol Med (Maywood), 239 (3), 366-75. https://doi.org/10.1177/1535370213518169  
  32. Gauthaman, K.; Fong, C. Y.; Bongso, A. (2010). ROCK inhibitor Y-27632 increases thaw-survival rates and pre-serves stemness and differentiation potential of human Whartons jelly stem cells after cryopreservation. Stem Cell Rev Rep, 6(4), 665-76.
  33. Giuliani, M.; Oudrhiri, N.; Lataillade, J. J. (2014). TLR ligands stimulation protects MSC from NK killing. Stem Cells, 32(1), 290-300. https://doi.org/10.1002/stem.1563 
  34. Glennie, S.; Lam, E. W.; Dazzi, F. (2005). Bone marrow mesenchymal stem cells induce division arrest energy of activated T cells. Blood, 105(7), 2821-7. https://pubmed.ncbi.nlm.nih.gov/15591115/  
  35. Gronthos, S.; Hay, S. J.; Shi, S.; Graves, S. E.  (2003). Molecular and cellular characterization of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116(9), 1827-35. https://doi.org/10.1242/jcs.00369  
  36. Govindasamy, V.; Ronald, V. S.; Abdullah, A. N.; Ab Aziz, Z. A. (2011). Differentiation of dental pulp stem cells into islet-like aggregates. J Dent Res. 90(5), 646-52.
  37. Hang, H.; Yu, Y.; Huang, Q. (2014).  Induction of highly functional hepatocytes from human umbilical cord mesenchymal stem cells by HNF4α transduction. PLoS One. 9(8), e104133.https://doi.org/10.1371/journal.pone.0104133.eCollection2014  
  38. Hatakeyama, A.; Uchida, S.; Utsunomiya, H. (2017). Isolation and Characterization of Syno-vial Mesenchymal Stem Cell Derived from Hip Joints: A Comparative Analysis with a Matched Control Knee Group. Stem Cells Int 2017, 9312329.
  39. Hilkens, P.; Gervois, P.; Fanton, Y. (2013). Effect of isolation methodology on stem cell properties and multiline age differentiation poten-tial of human dental pulp stem cells. Cell Tissue Res. 353(1), 65-78. https://doi.org/10.1007/s00441-013-1630-x 
  40. Hou, T.; Xu, J.; Wu, X. (2009). Umbilical cord Whartons Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. Tissue Eng Part: A 15(9), 2325-34.
  41. Huang, G. T.; Gronthos, S.; Shi, S. (2009).  Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res. 88(9), 792-806. https://doi.org/10.1177/0022034509340867  
  42. Huang, S. J.; Fu, R. H.; Liu, S. (2013). Adipose-derived stem cells: isolation, characterization, and differentiation potential. Cell Transplant 22(4), 701-9. https://pubmed.ncbi.nlm.nih.gov/23068312/  
  43. Int Anker, P. S.; Scherjon, S. A.; Kleijburg-van der Keur, C. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 102(4), 1548-9
  44. Jankowski, R. J.; Deasy, B. M.; Huard, J. (2002) Muscle-derived stem cells. Gene Ther, 9(10), 642-7. https://doi.org/10.1038/sj.gt.3301719 
  45. Jiang, X. X.; Zhang, Y.; Mao, N. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105(10), 4120-6.  
  46. Jiao, F.; Wang, J.; Wang, X. (2012). Human mesenchymal stem cells derived from limb bud can differentiate into all three embryonic germ layers lineages. Cell Reprogram. 14(4), 324-33. https://doi.org/10.1089/cell.2012.0004  
  47. Johnstone, B.; Hering, T. M.; Yoo, J. U. (1998). In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res, 238(1), 265-72.
  48. Kanafi, M. M.; Gupta, S.; Bhonde, R. R. (2013). Transplantation of islet-like cell clusters derived from human dental pulp stem cells restores normoglycemia in diabetic mice. Cytotherapy. 15(10), 1228-36. https://doi.org/10.1016/j.jcyt.2013.05.008  
  49. Kang, S. K.; Lee, D. H.; Jung, J. S. (2003). Improvment of neurological deficits by intra-cerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp Neurol 183(2), 355-66. 
  50. https://pubmed.ncbi.nlm.nih.gov/14552877/  
  51. Karystinou, A.; Kurth, T. B.; Wackerhage, H. (2009). Distinct mesenchymal progenitor cell subsets in the adult human synovium. Rheu-matology (Oxford) 48(9), 1057-64.
  52. Kim, N.; Cho, S. G., (2013). Clinical applications of mesenchymal stem cells. Korean J Intern Med 28(4), 387-402. https://doi.org/10.3904/kjim.2013.28.4.387  
  53. Kuroda, Y.; Kitada, M.; Wakao, S. (2010). Uni-que multi-potent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci, USA 107(19), 8639-43.
  54. La Rocca, G.; Loria, T.; Lo M. (2009). Isolation and characterization of Oct-4+/HLA-G+ mesen-chymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Hist Cell Biol. 131(2), 267-82. https://doi.org/10.3727/096368915X686841  
  55. Li, H.; Zacharaki, D.; Lim, H. C.; Scheding, S. (2016). Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann N Y Acad Sci. 1370(1), 109-18.
  56. Lin, C. S.; Lin, G.; Lue, T. F. (2012). Is CD34 truly a negative marker for mesenchymal stromal cells? Cytotherapy, 14(10), 1159-63. https://doi.org/10.3109/14653249.2012.729817  
  57. Lv, F. J.; Tuan, R. S.; Cheung, K. M.; Leung, V. Y. (2014). Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells, 32(6), 1408-19. 
  58. Mabuchi, Y.; Harada, S.; Niibe, K. (2013). LNGFR(+)THY-1(+)VCAM-1(hi+) cells reveal functionally distinct subpopulations in mesen-chymal stem cells. Stem Cell Reports, 1(2), 152-65. https://doi.org/10.1007/s12185-015-1921-y 
  59. Maijenburg, M. W.; Kleijer, M.; Voermans, C. (2012). The composition of the mesenchymal stromal cell compartment in human bone marrow changes during development and aging. Haema-tologica, 97 (2), 179-83.
  60. Mamidi, M. K.; Singh, G.; Thrichelvam, S. T. (2012). Comparative cellular and molecular ana-lyses of pooled bone marrow multipotent mesen-chymal stromal cells during continuous passaging and after successive cryopreservation. J Cell Biochem. 113(10), 3153-64. https://doi.org/10.1002/jcb.24193  
  61. Maria, A. T.; Noël, D.; Guilpain, P. (2017). Adi-pose-Derived Mesenchymal Stem Cells in Auto-immune Disorders: State of the Art and Pers-pectives for Systemic Sclerosis. Clin Rev Allergy Immunol 52(2), 234-259.
  62. Masuda, H.;  Rao, J. R.; Gargett, C. E. (2012). A novel marker of human endometrial mesen-chymal stem-like cells. Cell Trans, 21(10), 2201- 14. https://doi.org/10.3727/096368911X637362  
  63. Mattar, P.; Bieback, K. (2015). Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mes-enchymal stromal cells. Front Immunol, 6, 560.
  64. Miao, Z.; Jin, J.; Zhang, X. (2006).  Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesen-chymal stem cells. Cell Biol Int. 30(9), 681-7. https://doi.org/10.1016/j.cellbi.2006.03.009 
  65. Moll, G.; Jitschin, R.; Sundberg, B. (2011).  Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One, 6(7), e21703. https://pubmed.ncbi.nlm.nih.gov/21747949/  
  66. Morito, T.; Hara, K.; Ju, Y. J.; Umezawa, A. (2008). Synovial fluid-derived mesenchymal stem cells increase after intra-articular ligament injury in humans. Rheumatology, 47(8), 1137-43. https://doi.org/10.1093/rheumatology/ken114 
  67. Munir, H.; Nash, G. B.; McGettrick, H. (2015). Analyzing the effects of stromal cells on the recruitment of leukocytes from flow. J Vis Exp, (95), e52480.
  68. Murphy, M. B.; Moncivais, K.; Caplan, A. I. (2013). Mesenchymal stem cells: environment-ally responsive therapeutics for regenerative medicine. Exp Mol Med, 45, e54. https://doi.org/10.1038/emm.2013.94 
  69. Mushahary, D.; Spittler, A.; Kasper, C. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 93(1), 19-31.
  70. Nauta, A. J.;  Lurvink, E.;  Fibbe, W. E. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol, 177 (4), 2080-7. https://doi.org/10.4049/jimmunol.177.4.2080 
  71. Orciani, M.; Morabito, C.; Di Primio, R. (2010). Functional characterization of calcium-signaling pathways of human skin-derived mesenchymal stem cells. Skin Pharma. Physiol, 23(3), 124-32. https://pubmed.ncbi.nlm.nih.gov/20051713/ 
  72. Otsuru, S.; Olson, T. S.; Horwitz, E. M. (2013).  Improved isolation and expansion of bone mar-row mesenhymal stromal cells using a novel marrow filter device. Cytotherapy. 15(2), 146-53. https://doi.org/10.1016/j.jcyt.2012.10.012  
  73. Pachón-Peña, G.; Yu, G.; Gimble, J. M. (2011). Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol, 226 (3), 843-51.https://doi.org/10.1002/jcp.22408  
  74. Paduano, F.; Marrelli, M.; Palmieri, F. (2016). CD146 Expression Influences Periapical Cyst Mesenchymal Stem Cell Properties. Stem Cell Rev Rep, 12(5), 592-603. https://pubmed.ncbi.nlm.nih.gov/27406247/  
  75. Pendleton, C.; Li, Q.; Yuan, K. (2013).  Mesen-chymal stem cells derived from adipose tissue vs bone marrow: in vitro comparison of their tro-pism towards gliomas. PLoS One. 8(3), e58198. https://doi.org/10.1371/journal.pone.0058198  
  76. Pérez-Silos, V.; Camacho-Morales, A.; Fuentes-Mera, L. (2016). Mesenchymal Stem Cells Sub-populations: Application for Orthopedic Regen-erative Medicine. Stem Cells Int 2016, 3187491.
  77. Phadnis, S. M.; Nair, P. D.; Hardikar, A. A. (2011). Human bone marrow-derived mesen-chymal cells differentiate and mature into endo-crine pancreatic lineage in vivo. Cytotherapy. 13(3), 279-93. https://doi.org/10.3109/14653249.2010.523108  
  78. Pilbauerová, N.; Suchánek, J., Soukup, T. (2019). Enzymatic Isolation, Amplification and Chara-cterization of Dental Pulp Stem Cells. Folia Biol (Praha), 65(3), 124-133.
  79. Pittenger, M. F.; Beck, S. C.; Mosca, J. D. (1999). Multi lineage potential of adult human mesenchymal stem cells. Science 284(5411), 143- 7. https://doi.org/10.1126/science.284.5411.143  
  80. Prabakar, K. R.; Pileggi, A.; Inverardi, L. (2012). Generation of glucose-responsive, insulin-pro-ducing cells from human umbilical cord blood-derived mesenchymal stem cells. Cell Transplant 21(6), 1321-39. https://pubmed.ncbi.nlm.nih.gov/22195604/  
  81. Psaltis, P. J.; Paton, S.; See, F.; Martin, S. (2010). Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 223(2), 530-40. https://doi.org/10.1002/jcp.22081 
  82. Quirici, N.; Scavullo, C.; de Girolamo, L. (2010). Anti-L-NGFR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue. Stem Cells Dev, 19(6), 915-25.
  83. Qu-Petersen, Z.; Deasy, B.; Ikezawa, M. (2002). Identification of a novel population of muscle stem cells in mice: potential for muscle regener-ation. J Cell Biol, 157(5), 851-64. https://doi.org/10.1083/jcb.200108150   
  84. Ranera, B.; Remacha, A. R.; Álvarez-Arguedas, S. (2013).  Expansion under hypoxic conditions enhances the chondrogenic potential of equine bone marrow-derived mesenchymal stem cells. Vet J. 195(2), 248-51.
  85. Rasmusson, I.; Ringdén, O.; Le Blanc, K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cyto-toxic T lymphocytes or natural killer cells. Trans-plantation, 76(8), 1208-13. https://doi.org/10.1097/01.tp.0000082540.43730.80 
  86. Raynaud, C. M.; Lis, R.; Rafii, A. (2012). Com-prehensive characterization of mesenchymal stem cells from human placenta and fetal membrane and their response to osteoactivin stimulation. Stem Cells Int. 2012, 658356.
  87. Riekstina, U.; Muiznieks, I.; Ancans, J. (2008).  Characterization of human skin-derived mesen-chymal stem cell proliferation rate in different growth conditions. Cytotechnology. 58(3), 153-62. https://doi.org/10.1007/s10616-009-9183-2 
  88. Rotter, N.; Oder, J.; Rohwedel, J. (2008). Isolation and characterization of adult stem cells from human salivary glands. Stem Cells Dev. 17(3), 509-18.
  89. Sacchetti, B.; Funari, A.; Saggio, I. (2007). Self-renewing osteoprogenitors in bone marrow sinu-soids can organize a hematopoietic microenviron-ment. Cell 131(2), 324-36. https://doi.org/10.1016/j.cell.2007.08.025  
  90. Saeedi, P.; Halabian, R.; Imani Fooladi, A. A. (2019). A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modi-fication strategies. Stem Cell Investig 6, 34.
  91. Safford, K. M.; Hicok, K. C.; Safford, S. D. (2002). Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun. 294(2), 371-9 https://doi.org/10.1016/s0006-291x(02)00469-2   
  92. Salehinejad, P.; Ali, A. M.; Omar, A. R.  (2012). Comparison of different methods for the isolation of mesenchymal stem cells from human um-bilical cord Whartons jelly. In Vitro Cell Dev Biol Anim 48(2), 75-83. 
  93. Sato, A.; Okumura, K.; Endo, F. (2007).  Isola-tion, tissue localization, and cellular charac-terization of progenitors derived from adult human salivary glands. Cloning Stem Cells. 9(2), 191-205. https://doi.org/10.1089/clo.2006.0054  
  94. Schwab, K. E.; Gargett, C. E. (2007). Co-expres-sion of two perivascular cell markers isolates mesenchymal stem-like cells from human endo-metrium. Hum Reprod, 22(11), 2903-11.
  95. Sharif IH, Mosaib MG, and Uddin ME.  (2019). Assessment and biomonitoring of the effect of rapeseeds oil on wister rat organs. Am. J. Pure Appl. Sci., 1(4), 20-29. https://doi.org/10.34104/ajpab.019.0192029 
  96. Shi, Q.; Yin, Z.; Wang, S. (2015). PGE2 Elevates IL-23 Production in Human Dendritic Cells via a cAMP Dependent Pathway. Medi. Inflam, 2015, 984690. https://doi.org/10.1155/2015/984690  
  97. Simmons, P. J.; Torok-Storb, B. (1991). Identi-fication of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood, 78(1), 55-62.
  98. Spaggiari, G. M.; Becchetti, S.; Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484-90. https://doi.org/10.1182/blood-2005-07-2775  
  99. Stock, P.; Dollinger, M. M.; Christ, B. (2014).  Human bone marrow mesenchymal stem cell-derived hepatocytes improve the mouse liver after acute acetaminophen intoxication by pre-venting progress of injury. Int J Mol Sci. 15(4), 7004-28
  100. Su, W. R.; Shi, S. H.; Le, A. D. (2011). Human gingiva-derived mesenchymal stromal cells attenuate contact hypersensitivity via prosta-glandin E2-dependent mechanisms. Stem Cells, 29(11), 1849-60. https://doi.org/10.1002/stem.738 
  101. Sui, Y.; Li, Y.; Hu, W. (2020) Generation of functional salivary gland tissue from human sub-mandibular gland stem/progenitor cells. Stem Cell Res Ther, 11(1), 127.  
  102. Tang, D. Q.; Wang, Q.; Yang, L. J. (2012).  In vitro generation of functional insulin-producing cells from human bone marrow-derived stem cells, but long-term culture running risk of malignant transformation. Am J Stem Cells. 1(2), 114-127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402040/  
  103. Thomson, J. A., Shapiro, S. S.; Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145-7.
  104. Timper, K.; Müller, B.; Zulewski, H. (2006).  Human adipose tissue-derived mesenchymal stem cells differentiate into insulin, somatostatin, and glucagon expressing cells. Biochem Biophys Res Commun. 341(4), 1135-40. https://doi.org/10.1016/j.bbrc.2006.01.072 
  105. Tormin, A.; Li, O.; Walsh, S. (2011). CD146 expression on primary non-hematopoietic bone marrow stem cells is correlated with in situ localization. Blood, 117(19), 5067-77.
  106. Tosh, D.; Strain, A. (2005). Liver stem cells--prospects for clinical use. J Hepatol, 42(1), S75-84. https://doi.org/10.1016/j.jhep.2004.12.009 
  107. Tsai, M. S.; Lee, J. L.; Hwang, S. M. (2004).  Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 19(6), 1450-6.
  108. Tuli, R.; Tuli, S.; Wang, M. L. (2003). Chara-cterization of multipotential mesenchymal pro-genitor cells derived from human trabecular bone. Stem Cells, 21(6), 681-93. https://doi.org/10.1634/stemcells.21-6-681  
  109. Tu, Z.; Li, Q.; Lin, F. (2010). Mesenchymal stem cells inhibit complement activation by sec-reting factor H. Stem Cells Dev 19(11), 1803-9.
  110. Ullah, I.; Subbarao, R. B.; Rho, G. J. (2015).  Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 35(2).
  111. Vaculik, C.; Bauer, W.; Iram, N. (2012). Human dermis harbors distinct mesenchymal stromal cell subsets. J Invest Dermatol 132(1), 563-74. https://doi.org/10.1038/jid.2011.355  
  112. Vasiliki, E. K. (2016). Mesenchymal Stem Cells Markers. Open Access J Neurol Neuro-surgery 1(3); 555561.
  113. Vishnubalaji, R.; Manikandan, M.; Al-Nba-heen, M. (2012). In vitro differentiation of human skin-derived multipotent stromal cells into putative endothelial-like cells. BMC Dev Biol 12, 7. https://doi.org/10.1186/1471-213X-12-7  
  114. Völlner, F.; Ernst, W.; Driemel, O. (2009). A two-step strategy for neuronal differentiation in vitro of human dental follicle cells. Differen-tiation. 77(5), 433-41. https://pubmed.ncbi.nlm.nih.gov/19394129/  
  115. Wagner, W.; Wein, F.; Frank-hauser, M. (2005). Comparative characteristics of mesen-chymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 33(11), 1402-16. https://doi.org/10.1016/j.exphem.2005.07.003  
  116. Wang, J.; Shi, S.; Wang, S. (2010). Stem cells from human-exfoliated deciduous teeth can differentiate into dopaminergic neuron-like cells. Stem Cells Dev. 19(9), 1375-83. https://doi.org/10.1089/scd.2009.0258  
  117. Wang, Y.; Wang, F.; Chen, H.; Zhang, K. (2014).  Human adipose-derived mesenchymal stem cells are resistant to HBV infection during differentiation into hepatocytes in vitro. Int J Mol Sci. 15(4), 6096-110.
  118. Weiss, A. R. R.; Dahlke, M. H. (2019). Immu-nomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs. Front Immunol 10, 1191. https://doi.org/10.3389/fimmu.2019.01191 
  119. Wilkins, A.; Ginty, M.; Hares, K.; Scolding, N. (2009). Human bone marrow-derived mesen-chymal stem cells secrete brain-derived neuro-trophic factor which promotes neuronal survival in vitro. Stem Cell Res. 3(1), 63-70.
  120. Xu, W.; Zhu, W.; Sun, X. (2004). Mesen-chymal stem cells from adult human bone mar-row differentiate into a cardio-myocyte pheno-type in vitro. Exp Biol Med. 229(7), 623-31. https://doi.org/10.1177/153537020422900706  
  121. Yañez, R.; Lamana, M. L.; García-Castro, J. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24 (11), 2582-91.
  122. Yazdekhasti; H, H. J., Rajabi Z, Aliakbari F. (2018). Germline cells derived from mesenchy-mal stem cells, with the focus on Whartons jelly. Asian Pacific J. of Reproduction, 7(2), 49-55. https://doi.org/10.4103/2305-0500.228013  
  123. Yoon, J. H.; Shin, S.; Jung, N. H.  (2013). Comparison of explants derived and enzymatic digestion-derived MSCs and the growth factors from Whartons jelly. Biomed Res Int 2013, 428726.
  124. Zhang, X.; Hirai, M.; Igura, K.; Satoh, (2011).  Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem. 112 (4), 1206-18. https://doi.org/10.1002/jcb.23042 
  125. Zhao, F.; Qu, Y.; Mu, D. (2014). Umbilical cord blood mesenchymal stem cells co-modified by TERT and BDNF: a novel neuroprotective therapy for neonatal hypoxic-ischemic brain damage. Int J Dev Neurosci. 38, 147-54. https://doi.org/10.1016/j.bbr.2019.01.012  
  126. Zhao, Q.; Ren, H., Han, Z. (2016). Mesen-chymal stem cells: Immunomodulatory capability and clinical potential in immune diseases. Journal of Cellular Immunotherapy, 2(1), 3-20.
  127. Zuk, P. A., (2010).The adipose-derived stem cell: looking back and looking ahead. Mol Biol Cell, 21(11), 1783-7. https://doi.org/10.1091/mbc.E09-07-0589  

Article Info:

Md. Ekhlas Uddin Dipu, Department of Biochemistry and Molecular Biology Gono Bishwabidalay, Dhaka, Bangladesh.

Received

June 9, 2021

Accepted

July 13, 2021

Published

July 28, 2021

Article DOI: 10.34104/ajpab.021.085097

Corresponding author

Kanwal Abbasi

Pharmaceutical Research Center, Pakistan Council of Scientific and Industrial Research (PCSIR), Laboratories Complex, Karachi-75280, Pakistan.

Cite this article

Abbasi K, Iqbal S, Bano S, Siddiqui K, and Muthiah L. (2021). More to explore; the mesenchymal stem cells (MSCs) major tissue sources, known surface markers and its immunomodulation properties. Am. J. Pure Appl. Sci., 3(4), 85-97. https://doi.org/10.34104/ajpab.021.085097 

Related Articles

Views
317
Download
716
Citations
Badge Img
Share